CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
对肿瘤微环境的深入理解以及将TIL（肿瘤浸润淋巴细胞）视为预后因素的认识，推动了免疫治疗领域的重大里程碑，并促成了许多癌症治疗的进展。然而，将这些知识转化为卵巢癌的临床成功仍然是一项挑战。免疫检查点抑制剂作为单药或与化疗联合的疗效一直不尽如人意，这促使人们探索与靶向药物（例如聚ADP核糖聚合酶抑制剂（PARP）和血管生成抑制剂）联合的替代策略以及新型免疫治疗方法。在不同组织学亚型中，透明细胞卵巢癌对免疫治疗表现出更高的敏感性。在卵巢癌背景下更深入地理解免疫耐药机制以及识别预测性生物标志物，仍然是亟待实现的核心发现基准。这对于成功确定免疫检查点抑制剂在卵巢癌治疗中的精准使用至关重要。
A deep understanding of the tumor microenvironment and the recognition of tumor-infiltrating lymphocytes as a prognostic factor have resulted in major milestones in immunotherapy that have led to therapeutic advances in treating many cancers. Yet, the translation of this knowledge to clinical success for ovarian cancer remains a challenge. The efficacy of immune checkpoint inhibitors as single agents or combined with chemotherapy has been unsatisfactory, leading to the exploration of alternative combination strategies with targeted agents (e.
g. , poly-ADP-ribose inhibitors (PARP)and angiogenesis inhibitors) and novel immunotherapy approaches. Among the different histological subtypes, clear cell ovarian cancer has shown a higher sensitivity to immunotherapy. A deeper understanding of the mechanism of immune resistance within the context of ovarian cancer and the identification of predictive biomarkers remain central discovery benchmarks to be realized. This will be critical to successfully define the precision use of immune checkpoint inhibitors for the treatment of ovarian cancer.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
